Aldeyra Therapeutics Statistics
Share Statistics
Aldeyra Therapeutics has 59.9M
shares outstanding. The number of shares has increased by 0.5%
in one year.
Shares Outstanding | 59.9M |
Shares Change (YoY) | 0.5% |
Shares Change (QoQ) | 0.27% |
Owned by Institutions (%) | 62.48% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 69,720 |
FTD / Avg. Volume | 3.88% |
Short Selling Information
The latest short interest is 4.75M, so 7.94% of the outstanding
shares have been sold short.
Short Interest | 4.75M |
Short % of Shares Out | 7.94% |
Short % of Float | 8.18% |
Short Ratio (days to cover) | 3.04 |
Valuation Ratios
The PE ratio is -5.31 and the forward
PE ratio is 19.14.
Aldeyra Therapeutics's PEG ratio is
-0.11.
PE Ratio | -5.31 |
Forward PE | 19.14 |
PS Ratio | 0 |
Forward PS | 0.7 |
PB Ratio | 4.18 |
P/FCF Ratio | -6.87 |
PEG Ratio | -0.11 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aldeyra Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.48,
with a Debt / Equity ratio of 0.22.
Current Ratio | 5.48 |
Quick Ratio | 5.48 |
Debt / Equity | 0.22 |
Debt / EBITDA | -0.25 |
Debt / FCF | -0.35 |
Interest Coverage | -31.21 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-6,205,716 |
Employee Count | 9 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.54% in the
last 52 weeks. The beta is 0.68, so Aldeyra Therapeutics's
price volatility has been higher than the market average.
Beta | 0.68 |
52-Week Price Change | -42.54% |
50-Day Moving Average | 2.86 |
200-Day Moving Average | 4.85 |
Relative Strength Index (RSI) | 47.09 |
Average Volume (20 Days) | 1,796,768 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -60.12M |
Net Income | -55.85M |
EBITDA | -60.12M |
EBIT | -57.78M |
Earnings Per Share (EPS) | -0.94 |
Full Income Statement Balance Sheet
The company has 54.53M in cash and 15.3M in
debt, giving a net cash position of 39.22M.
Cash & Cash Equivalents | 54.53M |
Total Debt | 15.3M |
Net Cash | 39.22M |
Retained Earnings | -450.11M |
Total Assets | 93.2M |
Working Capital | 77M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -43.21M
and capital expenditures 0, giving a free cash flow of -43.21M.
Operating Cash Flow | -43.21M |
Capital Expenditures | n/a |
Free Cash Flow | -43.21M |
FCF Per Share | -0.73 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |